The effectiveness of new antibiotics in the treatment of community-acquired pneumonia

Nikodem Trzcina; Joanna Wieczfińska; Rafał Pawliczak

doi:10.5114/pja.2023.129082

eISSN: 2391-6052
ISSN: 2353-3854

Alergologia Polska - Polish Journal of Allergology

Current issue Archive Manuscripts accepted About the journal Supplements Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2023
vol. 10

Send email

Copy url:

abstract:

Review paper

The effectiveness of new antibiotics in the treatment of community-acquired pneumonia

Nikodem Trzcina

¹

,

Joanna Wieczfińska

¹

,

Rafał Pawliczak

¹

Zakład Immunopatologii, Oddział Nauk Biomedycznych, Wydział Lekarski, Uniwersytet Medyczny w Łodzi, Polska

Alergologia Polska – Polish Journal of Allergology 2023; 10, 2: 112–117

DOI: https://doi.org/10.5114/pja.2023.129082

Online publish date: 2023/06/30

View full text Get citation

PlumX metrics:

Community-acquired pneumonia (CAP), defined as acute pulmonary parenchymal infection acquired outside the hospital, remains one of the most common causes of hospitalization and death, especially among people over 65 and those with impaired immunity. This is a serious problem due to aging societies in many countries and comorbidities. Despite the development of diagnostic methods, in half of the patients with CAP, the etiology cannot be determined, which emphasizes the importance of empirical treatment and the risk of increasing antibiotic resistance to available preparations. In recent years, new antibiotics have been approved for the treatment of CAP, which may significantly improve the possibilities of empirical treatment of CAP.

keywords:

The effectiveness of new antibiotics in the treatment of community-acquired pneumonia

Nikodem Trzcina 1 , Joanna Wieczfińska 1 , Rafał Pawliczak 1

community-acquired pneumonia, antibiotics, lefamulin, delafloxacin, omadacycline, ceftobiprole

Nikodem Trzcina

¹

,

Joanna Wieczfińska

¹

,

Rafał Pawliczak

¹